Fintel reports that on June 3, 2025, Oppenheimer initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Outperform ...

Any point can be considered low -- even after massive gains -- provided there is plenty of upside left. That brings us to ...

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shares of IBD 50 stock Axsome Therapeutics tumbled Tuesday after the biotech reported mixed results for its drug, Sunosi, in adults with attention deficit hyperactivity disorder. The company ...

Get the annual and quarterly balance sheet of Axsome Therapeutics, Inc. (AXSM) including details of assets, liabilities and shareholders' equity.

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m, up 81% YoY, but net loss increased to $(64.6m). Despite positive market response and promising pipeline candidates ...

Axsome Therapeutics, Inc. has announced a new $570 million term loan and revolving credit facility with Blackstone Life Sciences and Blackstone Credit & Insurance, which replaces its previous term ...

HC Wainwright reissued their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report report published on Thursday morning,Benzinga reports. They currently ...

In January, Axsome Therapeutics reported preliminary Auvelity net product sales are expected to be approximately $92.6 million and $291.4 million for the fourth quarter and full year of 2024 ...

NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the first ...